Mostrar el registro sencillo del ítem

dc.contributor.author
Zorzopulos, Jorge
dc.contributor.author
Opal, Steven M.
dc.contributor.author
Hernando Insúa, Andrés
dc.contributor.author
Rodriguez, Juan M.
dc.contributor.author
Elías, Fernanda
dc.contributor.author
Fló, Juan
dc.contributor.author
López, Ricardo A.
dc.contributor.author
Chasseing, Norma Alejandra
dc.contributor.author
Lux, Victoria Adela R.
dc.contributor.author
Coronel, Maria Florencia
dc.contributor.author
Franco, Raul
dc.contributor.author
Montaner, Alejandro D
dc.contributor.author
Horn, David L
dc.date.available
2017-09-19T15:07:35Z
dc.date.issued
2017-03-26
dc.identifier.citation
Zorzopulos, Jorge; Opal, Steven M.; Hernando Insúa, Andrés; Rodriguez, Juan M.; Elías, Fernanda; et al.; Immunomodulatory oligonucleotide IMT504: effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapy; Baishideng Publishing Group Inc; World Journal of Stem Cells; 9; 3; 26-3-2017; 45-67
dc.identifier.issn
1948-0210
dc.identifier.uri
http://hdl.handle.net/11336/24562
dc.description.abstract
The immune responses of humans and animals to insults (i.e., infections, traumas, tumoral transformation and radiation) are based on an intricate network of cells and chemical messengers. Abnormally high inflammation immediately after insult or abnormally prolonged pro-inflammatory stimuli bringing about chronic inflammation can lead to life-threatening or severely debilitating diseases. Mesenchymal stem cell (MSC) transplant has proved to be an effective therapy in preclinical studies which evaluated a vast diversity of inflammatory conditions. MSCs lead to resolution of inflammation, preparation for regeneration and actual regeneration, and then ultimate return to normal baseline or homeostasis. However, in clinical trials of transplanted MSCs, the expectations of great medical benefit have not yet been fulfilled. As a practical alternative to MSC transplant, a synthetic drug with the capacity to boost endogenous MSC expansion and/or activation may also be effective. Regarding this, IMT504, the prototype of a major class of immunomodulatory oligonucleotides, induces in vivo expansion of MSCs, resulting in a marked improvement in preclinical models of neuropathic pain, osteoporosis, diabetes and sepsis. IMT504 is easily manufactured and has an excellent preclinical safety record. In the small number of patients studied thus far, IMT504 has been well-tolerated, even at very high dosage. Further clinical investigation is necessary to demonstrate the utility of IMT504 for resolution of inflammation and regeneration in a broad array of human diseases that would likely benefit from an immunoprotective/immunoregenerative therapy.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Baishideng Publishing Group Inc
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
Imt504
dc.subject
Mesenchymal Stem Cells
dc.subject.classification
Bioquímica y Biología Molecular
dc.subject.classification
Medicina Básica
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
dc.subject.classification
Patología
dc.subject.classification
Medicina Básica
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
dc.title
Immunomodulatory oligonucleotide IMT504: effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapy
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2017-09-08T20:19:06Z
dc.identifier.eissn
1948-0210
dc.journal.volume
9
dc.journal.number
3
dc.journal.pagination
45-67
dc.journal.pais
Estados Unidos
dc.description.fil
Fil: Zorzopulos, Jorge. Immunotech; Argentina
dc.description.fil
Fil: Opal, Steven M.. Memorial Hospital of Rhode Island; Estados Unidos. Alpert Medical School; Estados Unidos
dc.description.fil
Fil: Hernando Insúa, Andrés. Fundación Pablo Cassara; Argentina
dc.description.fil
Fil: Rodriguez, Juan M.. Fundación Pablo Cassara; Argentina
dc.description.fil
Fil: Elías, Fernanda. Fundación Pablo Cassara; Argentina
dc.description.fil
Fil: Fló, Juan. Immunotech; Argentina
dc.description.fil
Fil: López, Ricardo A.. Imunotech; Argentina
dc.description.fil
Fil: Chasseing, Norma Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
dc.description.fil
Fil: Lux, Victoria Adela R.. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
dc.description.fil
Fil: Coronel, Maria Florencia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
dc.description.fil
Fil: Franco, Raul. Imunotech; Argentina
dc.description.fil
Fil: Montaner, Alejandro D. Fundación Pablo Cassara; Argentina
dc.description.fil
Fil: Horn, David L. David Horn Llc; Estados Unidos
dc.journal.title
World Journal of Stem Cells
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/http://www.wjgnet.com/1948-0210/full/v9/i3/45.htm
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/ 10.4252/wjsc.v9.i3.45
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368622/
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/pmid/28396715


Archivos asociados

 

Comunidades y colecciones

  • Articulos(IBYME) [1164]
    Articulos de INST.DE BIOLOGIA Y MEDICINA EXPERIMENTAL (I)

Mostrar el registro sencillo del ítem